This site is intended for healthcare professionals only

In association with the Cardiorenal Forum

Articles

  • Man taking pill

    SGLT2i kidney outcome trial participants vs a real-world population

  • SGLT2 inhibitors versus GLP-1 receptor agonists for renal patients: does it matter?

  • Pharmacist considering medications

    Novel antidiabetes drugs improve composite renal outcomes

  • Heart monitor screen

    Pharmacotherapy for weight management in HFpEF: Do we have to lose big to win small?

  • Man taking pill with water

    Dapagliflozin and cardiovascular risks with worsening renal function

  • Rack of blood sample tubes

    Cardiorenal biomarkers in the CREDENCE trial

  • Glucose-lowering medications and comparative kidney outcomes in type 2 diabetes

  • Sodium–glucose cotransporter 2 inhibitors in heart failure: does it matter how they work?

  • EMPA-VISION: Cardiac energy in people with heart failure taking empagliflozin

alt

For the latest news and articles
Sign up to Renal Review newsletters

Subscribe